Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALLERGAN PLC

(AGN)
  Report
SummaryNewsCompanyFinancials 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Botox maker Allergan's revenue forecast misses estimates, shares drop

01/29/2019 | 10:18am EST
FILE PHOTO - The Allergan logo is seen in this photo illustration in Singapore

(Reuters) - Allergan Plc on Tuesday forecast 2019 revenue below expectations on looming competition for some of its top drugs, and shelved plans to sell its women's health business.

The Botox maker's shares fell 6 percent to $149.20

in early trading.

Chief Executive Officer Brent Saunders put the company's women's health and infectious disease units on the block in May to focus on growing its core businesses that include medical aesthetics and eye care.

"For Women's Health, we have concluded that the highest value proposition for this business at this time is to continue managing it and optimizing it," Saunders said on a post-earnings call with analysts.

The CEO also said the anti-infectives business would "more likely than not" be sold over the near term.

In the fourth quarter, the company recorded pretax impairment charges of $5.4 billion (4.1 billion pounds), including a goodwill write-off related to the anti-infectives unit and a charge from lower-than-expected sales of its double chin treatment Kybella, which it bought at a premium of 24 percent in 2015.

"Given questions around the past deals and management's ability to execute, we think the Street will likely view this large write-off negatively," Credit Suisse analyst Vamil Divan said in a note.

Allergan has warned that profits will be hurt once generics of Restasis hit the market, after a bid to protect that drug's patents met regulatory scrutiny. Once a drug begins facing competition from multiple generic versions, it can quickly lose more than 80 percent of sales.

Sales of Restasis, the company's second-most important drug, fell 17.7 percent, while sales of Botox, Allergan's best-selling product, rose 9.4 percent.

Botox's market-leading position in aesthetics and as an anti-wrinkle treatment has helped the company power past analysts' profit estimates for much of the past, but concerns remain about the competitive threat from two smaller companies' upcoming rival products.

Allergan said last year it was doubling its investment in direct-to-consumer ad spending and beefing up its sales force as companies like Revance Therapeutics Inc and Evolus Inc vie to wrest market share with rival treatments to Botox.

Excluding items, Allergan earned $4.29 per share in the fourth quarter, beating analysts' expectations of $4.15, according to Refinitiv data.

The company, which authorized a new $2 billion share buyback program, said net revenue fell 5.7 percent o $4.1 billion.

Allergan forecast 2019 revenue of $15.00 billion to $15.30 billion, compared with analysts' estimates of $15.40 billion.

(Reporting by Manas Mishra in Bengaluru; Editing by Maju Samuel and Sweta Singh)

By Manas Mishra


ę Reuters 2019
Stocks mentioned in the article
ChangeLast1st jan.
ALLERGAN PLC 0.00%End-of-day quote.0.97%
BEST INC. -5.28% 0.72 Delayed Quote.-10.73%
NEXT PLC 0.19% 7444 Delayed Quote.-8.83%
All news about ALLERGAN PLC
2021Allergan plc completed the acquisition of Soliton, Inc. for approximately $570 million.
CI
2021Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related B..
AQ
2021Allergan Aesthetics to Present Data from its Aesthetic Portfolio at the 2021 American S..
CI
2021Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the ..
AQ
2021Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the ..
CI
2021HAGENS BERMAN : Law Firm Investigating Permanent Injuries and Disfigurement from Botched C..
BU
2021ABBVIE : Allergan - FDA Approves Expanded BOTOX Label to Include Eight New Muscles to Trea..
AQ
2021ABBVIE : Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfo..
AQ
2021Allergan plc entered into a definitive agreement to acquire Soliton, Inc. for approxima..
CI
2021STAMP DUTY BATTLE : Abbvie Wins Appeal Against Ç587m Irish Stamp Duty
AQ
More news
Analyst Recommendations on ALLERGAN PLC
More recommendations
Financials (USD)
Sales 2020 15 208 M - -
Net income 2020 - - -
Net Debt 2020 - - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 63 649 M 63 649 M -
Capi. / Sales 2020 4,19x
Capi. / Sales 2021 4,02x
Nbr of Employees 17 400
Free-Float -
Income Statement Evolution
Managers and Directors
Robert A. Michael President & Director
Scott Reents Director
Ryan Quigley Director
Andres Rodrigo Director
Basil Blakeney Director
Sector and Competitors
1st jan.Capi. (M$)
ALLERGAN PLC0.97%63 659
JOHNSON & JOHNSON-2.01%441 302
ROCHE HOLDING AG-8.68%304 745
PFIZER, INC.-11.02%294 900
ABBVIE INC.-1.71%235 287
ELI LILLY AND COMPANY-13.31%217 093